

CLAIMS: What is claimed is:

1. A composition comprising a glycosylated interferon-beta coupled to a non-naturally-occurring polymer, said polymer comprising a polyalkylene glycol moiety.
2. The composition of claim 1, wherein the polyalkylene moiety is coupled to the interferon-beta by way of a group selected from an aldehyde group, a maleimide group, a vinylsulfone group, a haloacetate group, plurality of histidine residues, a hydrazine group and an aminothiol group.
3. The composition of claim 1, wherein the glycosylated interferon-beta is interferon-beta-1a and is more active than interferon-beta-1b when measured in an antiviral assay.
4. The composition of claim 3, wherein the interferon-beta-1a retains 0.5 to 1 times the potency of interferon-beta-1a lacking said polymer, as measured in an antiviral assay.
5. The composition of claim 1, wherein the interferon-beta is an interferon-beta-1a fusion protein.
6. The composition of claim 5, wherein the interferon-beta-1a fusion protein comprises a portion of an immunoglobulin molecule.
7. The composition of claims 1 or 5, wherein the interferon beta is a mutant interferon beta having at least one of the following properties: (a) the mutant has a higher antiviral activity than wild type inteferon-beta-1a, wherein the antiviral activity is measured by viral induced lysis of cells; (b) the mutant has, relative to wild type interferon-beta-1a, greater antiviral activity than antiproliferative activity; (c) the mutant binds interferon receptor but has, when compared to wild type interferon-beta-1a, lowered antiviral activity and lowered antiproliferative activity relative to receptor binding activity.
8. A physiologically active interferon-beta composition comprising a physiologically active interferon-beta 1a coupled to a polymer comprising a polyalkylene glycol moiety, wherein the physiologically active interferon-beta 1a and the polyalkylene glycol moiety are arranged such that the physiologically

active interferon-beta 1a in the physiologically active interferon-beta composition has an enhanced activity relative to physiologically active interferon-beta 1b, when measured by an antiviral assay.

9. The composition of claim 8, wherein the interferon-beta-1a is coupled to the polymer at a site on the interferon-beta-1a that is an N-terminal end.
10. The composition of claim 8, wherein the interferon-beta-1a is coupled to the polymer at a site on the interferon-beta-1a that is at or near the C-terminal end.
11. The composition of claim 8, wherein the interferon-beta-1a is coupled to the polymer at a site by way of a glycan moiety of the interferon-beta-1a.
12. The composition of claim 8, wherein the interferon-beta-1a is an interferon-beta-1a fusion protein.
13. The composition of claim 12, wherein the interferon-beta-1a fusion protein comprises a portion of an immunoglobulin molecule.
14. The composition of claims 8 or 12, wherein the interferon-beta-1a is a mutant interferon-beta-1a having at least one of the following properties: (a) the mutant has a higher antiviral activity than wild type inteferon beta 1a, wherein the antiviral activity is measured by viral induced lysis of cells; (b) the mutant has, relative to wild type interferon-beta-1a, greater antiviral activity than antiproliferative activity; (c) the mutant binds interferon receptor but has, when compared to wild type interferon-beta-1a, lowered antiviral activity and lowered antiproliferative activity relative to receptor binding activity.
15. A physiologically active interferon-beta composition comprising a physiologically active glycosylated interferon-beta N-terminally coupled to a polymer comprising a polyalkylene glycol moiety, wherein the physiologically active interferon-beta and the polyalkylene glycol moiety are arranged such that the physiologically active interferon-beta in the physiologically active interferon-beta composition has substantially similar activity relative to physiologically active interferon-beta lacking said moiety, when measured by an antiviral assay.
16. The composition of claim 15, wherein the interferon-beta is coupled to the polymer at a site on the interferon-beta that is an N-terminal end.

17. The composition of claim 15 wherein the interferon-beta is coupled to the polymer at a site on the interferon-beta that is at or near the C-terminal end.
18. The composition of claim 15, wherein the interferon-beta is coupled to the polymer at a site by way of a glycan moiety on the interferon-beta.
- 5 19. The composition of claim 15, wherein the interferon-beta is an interferon beta fusion protein.
20. The composition of claim 19, wherein the interferon beta fusion protein comprises a portion of an immunoglobulin molecule.
21. The composition of claims 15 or 19 wherein the glycosylated interferon beta is a mutant interferon beta having at least one of the following properties: (a) the mutant has a higher antiviral activity than wild type inteferon beta 1a, wherein the antiviral activity is measured by viral induced lysis of cells; (b) the mutant has, relative to wild type interferon-beta-1a, greater antiviral activity than antiproliferative activity; (c) the mutant binds interferon receptor but has, when compared to wild type interferon-beta-1a, lowered antiviral activity and lowered antiproliferative activity relative to its receptor binding activity.
- 10 22. A stable, aqueously soluble, conjugated interferon-beta 1a complex comprising a interferon-beta 1a coupled to a polyethylene glycol moiety, wherein the interferon-beta 1a is coupled to the polyethylene glycol moiety by a labile bond, wherein the labile bond is cleavable by biochemical hydrolysis and/or proteolysis.
- 20 23. A interferon-beta composition according to claims 1, 15 or 22, wherein the polymer has a molecular weight of from about 5 to about 40 kilodaltons.
24. A pharmaceutical composition comprising the interferon-beta composition of claim 23.
- 25 25. A method of treating a potential or developed condition or disease state in a mammalian subject with a interferon-beta 1a effective therefore, comprising administering to the subject an effective amount of an interferon-beta 1a composition comprising said interferon-beta 1a coupled to a polyethylene glycol moiety.
- 30 26. The method of claim 25, wherein the interferon-beta-1a is coupled to the polymer at a site on the interferon-beta-1a that is an N-terminal end.

27. The method of claim 25, wherein the interferon-beta-1a is coupled to the polymer at a site on the interferon-beta-1a that is at or near the C-terminal end.
28. The method of claim 25, wherein the interferon-beta-1a is coupled to the polymer at a site by way of a glycan moiety on the interferon-beta-1a.
- 5 29. The method of claim 25, wherein the interferon-beta-1a is an interferon-beta-1a fusion protein.
30. The method of claim 29, wherein the interferon-beta-1a fusion protein comprises a portion of an immunoglobulin molecule.
31. The method of claims 25 and 29, wherein the interferon-beta-1a is a mutant
10 interferon-beta-1a having at least one of the following properties: (a) the mutant has a higher antiviral activity than wild type inteferon beta 1a, wherein the antiviral activity is measured by viral induced lysis of cells; (b) the mutant has, relative to wild type interferon-beta-1a, greater antiviral activity than
15 antiproliferative activity; (c) the mutant binds interferon receptor but has, when compared to wild type interferon-beta-1a, lowered antiviral activity and lowered antiproliferative activity relative to its receptor binding activity.
32. A method of prolonging the activity of interferon-beta-1a in an in vivo or in vitro system, comprising coupling said interferon-beta 1a to a non-naturally-occurring polymer moiety to yield a coupled polymer-interferon-beta 1a composition, and
20 introducing the coupled polymer-interferon-beta composition to the in vivo or in vitro system.
33. The method of claim 32, wherein the interferon-beta-1a is coupled to the polymer at a site on the interferon-beta-1a that is an N-terminal end.
34. The method of claim 32, wherein the interferon-beta-1a is coupled to the polymer
25 at a site on the interferon-beta-1a that is at or near C-terminal end.
35. The method of claim 32, wherein the interferon-beta-1a is coupled to the polymer at a site by way of a glyan moiety on the interferon-beta-1a.
36. The method of claim 32, wherein the interferon-beta-1a is an interferon-beta-1a fusion protein.
- 30 37. The method of claim 36, wherein the interferon-beta-1a fusion protein comprises a portion of an immunoglobulin molecule.

38. The method of claims 32 and 36, wherein the interferon-beta-1a is a mutant
interferon-beta-1a having at least one of the following properties: (a) the mutant
has a higher antiviral activity than wild type inteferon beta 1a, wherein the
antiviral activity is measured by viral induced lysis of cells; (b) the mutant has,
5 relative to wild type interferon-beta-1a, greater antiviral activity than
antiproliferative activity; (c) the mutant binds interferon receptor but has, when
compared to wild type interferon-beta-1a, lowered antiviral activity and lowered
antiproliferative activity relative to its receptor binding activity.
39. The method of claim 32, wherein the polymer comprises a polyalkylene glycol.
- 10 40. A method of inhibiting angiogenesis in a subject, comprising administering to a
subject an effective amount of the composition of claim 23.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50